Alterity Therapeutics Limited
ATHE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ATHE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATHE
Alterity Therapeutics Limited is an early-to-mid-stage biotechnology company focused on developing therapies for neurodegenerative diseases, with its lead candidate ATH434 targeting Multiple System Atrophy (MSA).
Key risk: Concentration risk on ATH434
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2025.
Tracking 2 clinical trials · 1 catalyst for Alterity Therapeutics Limited.
Alterity Therapeutics Limited is an early-to-mid-stage biotechnology company focused on developing therapies for neurodegenerative diseases, with its lead candidate ATH434 targeting Multiple System Atrophy (MSA).
- Lead candidate ATH434 has achieved FDA alignment on a registrational Phase 3 program for MSA following a successful End-of-Phase 2 meeting [sec · filed 2026-08-28].
- Cash and equivalents of $33.2M as of 2025-06-30 [sec].
- Net loss of $23,441,790 for the year ended June 30, 2026, compared to $12,147,828 in the prior year [sec · filed 2026-08-28].
- All product candidates are in discovery or early-to-mid-stage development, with no products commercialized to date [sec · filed 2026-08-28].
What works
- Successful FDA End-of-Phase 2 meeting with alignment on key elements of the registrational Phase 3 program for ATH434 in MSA [sec · filed 2026-08-28].
- Strong cash position of $33.2M as of 2025-06-30, with a history of successfully raising funds via equity capital raisings [sec · filed 2026-08-28].
- Intellectual property for product candidates is owned by the company, with no current need for enabling technology licenses [sec · filed 2026-08-28].
What to weigh
- History of operating losses with a net loss of $23,441,790 for the year ended June 30, 2026, and expects to incur substantial and increasing losses for the next several years [sec · filed 2026-08-28].
- Business is concentrated around ATH434, making it vulnerable to setbacks in clinical development, regulatory strategy, or financing [sec · filed 2026-08-28].
- Clinical trials are expensive and time-consuming, with uncertain outcomes; early results may not predict later-stage success [sec · filed 2026-08-28].
- As a foreign private issuer listed on Nasdaq, there are risks related to enforceability of U.S. judgments and compliance with corporate governance standards [sec · filed 2026-08-28].
From the filings
Quoted directly from source documents.
FDA alignment on Phase 3 program for ATH434 in MSA
“we disclosed the successful outcome of our End-of-Phase 2 (EOP2) meeting with the FDA, achieving alignment on the key elements of our registrational Phase 3 program for ATH434 in MSA”
SEC filings · August 28, 2026
Net loss for fiscal year 2026
“net loss of $ 23,441,790 in the year ended June 30, 2026”
SEC filings · August 28, 2026
History of operating losses and reliance on capital raises
“We have a history of operating losses and will continue to incur losses whilst conducting clinical trials. However, we also have a history of successfully raising funds via equity capital raisings”
SEC filings · August 28, 2026
No products commercialized to date
“We have not commercialised any products to date”
SEC filings · August 28, 2026
Catalyst timeline
- 2040-09-01 · Patent_Expiry · QDOLO — Patent/Exclusivity Expiry: QDOLO — Patent expiry for QDOLO, which may affect exclusivity for that product.
Risks & what to watch (4)›
Key risks
- Concentration risk on ATH434 — Any setback in clinical development, regulatory strategy, or financing of ATH434 could materially harm the business [sec · filed 2026-08-28].
- History of operating losses — Net loss of $23.4M for fiscal 2026; expects substantial and increasing losses for several years [sec · filed 2026-08-28].
- Clinical trial uncertainty — Clinical trials are expensive, time-consuming, and outcomes are uncertain; early results may not predict later-stage success [sec · filed 2026-08-28].
- Foreign issuer and Nasdaq risks — Enforceability of U.S. judgments may be difficult; subject to home country governance practices instead of certain Nasdaq requirements [sec · filed 2026-08-28].
What to watch
- Initiation and enrollment of the registrational Phase 3 trial for ATH434 in MSA [sec · filed 2026-08-28].
- Ability to raise additional capital to fund Phase 3 development and ongoing operations [sec · filed 2026-08-28].
- Any updates on competitive landscape, particularly from other α-synuclein targeting therapies like Exidavnemab [sec · filed 2026-08-28].
- Financial performance and cash runway updates in future SEC filings [sec · filed 2026-08-28].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Alterity Therapeutics Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alterity Therapeutics Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.09
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~5116d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$424K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 58,382 | $203K |
| greenleaf trust | 32,000 | $111K |
| citadel advisors llc | 20,077 | $71K |
| bnp paribas financial markets | 6,809 | $24K |
| rhumbline advisers | 1,970 | $7K |
| gamma investing llc | 1,856 | $6K |
| osaic holdings, inc. | 68 | $240 |
| blue trust, inc. | 40 | $139 |
| farther finance advisors, llc | 22 | $80 |
| corecap advisors, llc | 21 | $73 |
Showing top 10 of 13 institutional holders of Alterity Therapeutics Limited. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.1%
- Days to cover
- 0.6
- Shares short
- 13,895
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATHE short interestFrequently asked questions
What is the AI investment thesis for Alterity Therapeutics Limited?
Alterity Therapeutics Limited is an early-to-mid-stage biotechnology company focused on developing therapies for neurodegenerative diseases, with its lead candidate ATH434 targeting Multiple System Atrophy (MSA).
What is Alterity Therapeutics Limited's next catalyst?
Alterity Therapeutics Limited's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: QDOLO" — expected September 1, 2040.
Who is the CEO of Alterity Therapeutics Limited?
Dr. David A. Stamler M.D. is the chief executive officer of Alterity Therapeutics Limited (ATHE).
Where is Alterity Therapeutics Limited headquartered?
Alterity Therapeutics Limited (ATHE) is headquartered in Melbourne, VIC, Australia.
What therapeutic areas does Alterity Therapeutics Limited focus on?
Alterity Therapeutics Limited develops therapies across Pain, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.